20MO Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician’s choice (TPC)Domenica Lorusso, V. Makker, Émeline Colomba et al.|Annals of Oncology|2022Cited by 1
AcSé immunotherapy trials: Anti-PD-1 therapy for adult patients with selected rare cancer typesAurélien Marabelle, Christophe Massard, Sylvie Chevret et al.|Annals of Oncology|2018Cited by 0